HUMAN CANCER BIOLOGY

6992 | Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tvankin, Marcia Klaassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri

7003 | Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

Perspective

6971 | DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Graham A. Colditz and John Crowley

6973 | DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

6985 | Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

Reviews

6971 | DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Graham A. Colditz and John Crowley

6973 | DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

6985 | Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe
**CANCER THERAPY: PRECLINICAL**

7047  **Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy**
Yuhuan Li, Li-Xin Wang, Puiyong Wang, Zhuhua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu

7058  **Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4**
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sherehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard

**IMAGING, DIAGNOSIS, PROGNOSIS**

7139  **Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival**
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutter, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

**CANCER THERAPY: CLINICAL**

7156  **Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors**
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164  **A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer**
Malsa Mohibatsh, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jaccquin Jones, Theresa Ferrara, Christopher B. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlim, and James L. Gulley
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy
Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohji Edamura, Ken-ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437
Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER
Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.